



## Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

August 25, 2025

FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:

**Cantor Global Healthcare Conference 2025** in New York, NY

Date: Wednesday, September 3, 2025

Live Webcast: 9:10 am EDT

*Management to participate in 1x1 meetings throughout the conference, which runs September 3-5, 2025.*

**H.C. Wainwright 27th Annual Global Investment Conference** in New York, NY

Date: Monday, September 8, 2025

Live Webcast: 1:00 pm EDT

*Management to participate in 1x1 meetings throughout the conference, which runs September 8-10, 2025.*

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Recordings will be available for up to 90 days following the conclusion of each webcast.

**About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA<sup>®</sup> (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA<sup>®</sup> TRIPLE PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA<sup>®</sup> DUAL PAK<sup>®</sup> (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the company's website at [www.phathompharma.com](http://www.phathompharma.com) follow on [LinkedIn](#) and [X](#).

**MEDIA CONTACT**

Nick Benedetto

1-877-742-8466

[media@phathompharma.com](mailto:media@phathompharma.com)

**INVESTOR CONTACT**

Eric Sciorilli

1-877-742-8466

[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.